NKGen Biotech, Inc. (NKGN)
NASDAQ: NKGN · Real-Time Price · USD
0.482
+0.042 (9.50%)
At close: Jan 21, 2025, 4:00 PM
0.471
-0.011 (-2.24%)
After-hours: Jan 21, 2025, 4:55 PM EST
NKGen Biotech Employees
NKGen Biotech had 63 employees as of December 31, 2023.
Employees
63
Change
n/a
Growth
n/a
Revenue / Employee
n/a
Profits / Employee
-$1,400,841
Market Cap
17.35M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 63 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 440,000 |
| Johnson & Johnson | 131,900 |
| Thermo Fisher Scientific | 122,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 89,900 |
| Novartis AG | 76,057 |
| Merck & Co. | 72,000 |
| Novo Nordisk | 64,319 |
NKGN News
- 7 weeks ago - NKGen Biotech Selected as Stalking Horse Bidder for NKMax - GlobeNewsWire
- 2 months ago - NKGen Biotech Receives Notifications From Nasdaq Related to Delayed Quarterly Report and Decision of the Nasdaq Hearings Panel - GlobeNewsWire
- 3 months ago - NKGen Biotech Presents Phase 1/2a Troculeucel Data in Alzheimer's Disease at the 17th Annual Clinical Trials on Alzheimer's Disease (CTAD) Conference - GlobeNewsWire
- 3 months ago - NKGen Biotech Announces Upcoming Presentation at the 16th World Stroke Congress (WSC 2024) - GlobeNewsWire
- 3 months ago - NKGen Biotech Announces Poster Presentations at the 17th Annual Clinical Trials on Alzheimer's Disease (CTAD) Conference - GlobeNewsWire
- 4 months ago - NKGen Biotech's Positive Phase 1 Clinical Data in Moderate Alzheimer's Disease Advances Troculeucel into Phase 2 with First Patient Dosed in Phase 1/2a Trial - GlobeNewsWire
- 5 months ago - NKGen Biotech to Present at the H.C. Wainwright 26th Annual Global Investment Conference - GlobeNewsWire
- 5 months ago - NKGen Biotech Receives Notification From Nasdaq Related to Delayed Quarterly Report - GlobeNewsWire